Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | GAK | O14976 | 2/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.37 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9627301 | 0.84 | AR (0.51) | ARTTRALBEGLN2KDM1A | |
| SCHEMBL29490258 | 0.81 | AR (0.66) | ARCYP11B2EGLN2CYP11B1KDM1A | |
| SCHEMBL509522 | 0.81 | AR (0.66) | ARCYP11B2EGLN2CYP11B1KDM1A | |
| SCHEMBL3571548 | 0.80 | TRPV4 (0.40) | ARTTRALBEGLN2SLC6A4 | |
| SCHEMBL31483652 | 0.80 | AR (0.39) | ARTTRALBCYP11B2EGLN2 | |
| SCHEMBL16957176 | 0.80 | GRM4 (0.34) | AR | |
| SCHEMBL431576 | 0.80 | EGFR (0.34) | ARALDH1A1GAK | |
| SCHEMBL17685351 | 0.80 | CYP3A4 (0.38) | ARALDH1A1 | |
| SCHEMBL15662789 | 0.79 | EIF4E (0.41) | ARTTRALBALDH1A1TRPV4 | |
| SCHEMBL24476682 | 0.78 | AR (0.54) | ARKDM4EUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137864-A1 | CANCER THERAPY WITH IL-2 CONJUGATES AND CHIMERIC ANTIGEN RECEPTOR THERAPIES | Synthorx, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-117776973-A | Preparation method of 4-formyl-3-methoxybenzonitrile | 山东特珐曼药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023122750-A1 | CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND CETUXIMAB | Synthorx, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122573-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022256534-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022076853-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2021263026-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | Synthorx, Inc. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| EP-0976722-B1 | BENZAMIDINE DERIVATIVES | AJINOMOTO KK (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | AR 4244/4885TTR 2183/4885ALB 4334/4885 |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | AR 229/4885TTR 4249/4885ALB 4777/4885 |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | AR 4244/4885TTR 2183/4885ALB 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.